人表皮生长因子受体2阳性乳腺癌中的免疫检查点阻断：在早期疾病中的作用是什么？
Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
作者信息
Solinas Cinzia, Fumagalli Debora, Dieci Maria Vittoria
机构信息
Medical Oncology, Azienda Tutela della Salute Sardegna, San Francesco Hospital, 08100 Nuoro, Italy.
Breast International Group, 1000 Brussels, Belgium.
出版信息
Cancers (Basel). 2021 Apr 1;13(7):1655. doi: 10.3390/cancers13071655.
The present commentary synthesizes the current evidence on the role of the immune response in HER2-positive breast cancer. It points out the strengths and weaknesses of the findings observed so far, particularly in the early setting, including the clinical significance of scoring tumor-infiltrating lymphocytes. A figure proposing research hypotheses for the implementation of immune checkpoint blockade use for patient candidates to neoadjuvant treatment is presented.
本述评综合了目前关于免疫反应在HER2阳性乳腺癌中作用的证据。它指出了迄今为止所观察到的研究结果的优势和不足，特别是在早期阶段，包括对肿瘤浸润淋巴细胞进行评分的临床意义。还展示了一个为新辅助治疗候选患者实施免疫检查点阻断提出研究假设的图表。
Zotero 插件